HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $65.00 target price on the stock.
Several other equities analysts have also recently commented on JSPR. BTIG Research initiated coverage on Jasper Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $90.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Evercore ISI restated an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. Royal Bank of Canada cut their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Finally, Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They set a “buy” rating and a $86.00 price objective for the company. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $74.86.
View Our Latest Analysis on Jasper Therapeutics
Jasper Therapeutics Stock Performance
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. On average, sell-side analysts anticipate that Jasper Therapeutics will post -4.16 EPS for the current year.
Hedge Funds Weigh In On Jasper Therapeutics
A number of large investors have recently added to or reduced their stakes in JSPR. Wolff Wiese Magana LLC bought a new position in shares of Jasper Therapeutics in the third quarter valued at $59,000. American Century Companies Inc. increased its position in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the last quarter. Rhumbline Advisers bought a new stake in Jasper Therapeutics in the second quarter valued at approximately $300,000. Bank of New York Mellon Corp bought a new position in shares of Jasper Therapeutics during the 2nd quarter worth approximately $740,000. Finally, Virtu Financial LLC acquired a new stake in Jasper Therapeutics during the first quarter worth approximately $306,000. Institutional investors own 79.85% of the company’s stock.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Read More
- Five stocks we like better than Jasper Therapeutics
- What is Put Option Volume?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.